



Development Solutions

July 20, 2012

Patrick McLaughlin
Executive Director, Anaheim Clinical Trials
1085 North Harbor Boulevard
Anaheim, CA 92801

Dear Mr. McLaughlin,

I would like to take this opportunity to thank your team for all your efforts on the Pfizer A7471018 hepatic impairment study. Since initiating your site on 23 April 2012, your team of Angela Aviles and Mike Gallardo worked extremely hard to complete enrollment on this project. Identifying potential subjects with the difficult inclusion criteria for this protocol has been challenging, yet your site has succeeded in randomizing six mild and four moderate subjects. This rapid enrollment has allowed us to close study enrollment nearly six months ahead of schedule. We truly appreciate your ability to locate appropriate subjects to enroll while minimizing screen failures. Mike and Angela have also been very attentive to keeping the Pfizer and ICON study team updated with study progress.

I would also like to acknowledge the work of Gaby Huizar in maintaining the regulatory documentation for this study. Gaby has provided updated regulatory documents in a timely manner and delivered additional records when requested to complete the Trial Master File. It is very welcomed knowing that the regulatory binder will be up to date and maintained in an orderly fashion at each visit. I truly appreciate the work she has done for us.

Again, thank you for all your efforts and I certainly look forward to the opportunity to work with your site again on future studies.

Sincerely,

Craig McLaughlin
Principal CRA
ICON Clinical Research
Office: 215-616-6847
Fax: 215-586-4037
E-mail: Craig.McLaughlin@iconplc.com